No

Diagnostic Agent, Gonadotrophic Hormone; Gonadotropin

Evaluation of the functional capacity and response of gonadotrophic hormones; evaluate abnormal gonadotropin regulation as in precocious puberty and delayed puberty. Lutrepulse®: Induction of ovulation in females with hypothalamic amenorrhea.

B

Known hypersensitivity to gonadorelin, women with any condition that could be exacerbated by pregnancy; patients who have ovarian cysts or causes of anovulation other than those of hypothalamic origin; any condition that may worsened by reproductive hormones

Hypersensitivity and anaphylactic reactions have occurred following multiple-dose administration; multiple pregnancy is a possibility; use with caution in women in whom pregnancy could worsen pre-existing conditions (eg, pituitary prolactinemia). Multiple pregnancy is a possibility with Lutrepulse®.

1% to 10%: Local: Pain at injection site

<1%: Flushing, lightheadedness, headache, rash, nausea, abdominal discomfort

Symptoms of overdose include abdominal discomfort, nausea, headache, flushing

Treatment is symptomatic

Decreased levels/effect: Oral contraceptives, digoxin, phenothiazines, dopamine antagonists

Increased levels/effect: Androgens, estrogens, progestins, glucocorticoids, spironolactone, levodopa

Factrel®: Prepare immediately prior to use; after reconstitution, store at room temperature and use within 1 day; discard unused portion

Lutrepulse®: Store at room temperature; reconstitute with diluent immediately prior to use and transfer to plastic reservoir. The solution will supply 90 minute pulsatile doses for 7 consecutive days (Lutrepulse® pump).

Stimulates the release of luteinizing hormone (LH) from the anterior pituitary gland

Peak effect: Maximal LH release occurs within 20 minutes

Duration of action: 3-5 hours

Half-life: 4 minutes

Diagnostic test: Children >12 years and Adults (female): I.V., S.C. hydrochloride salt: 100 mcg administered in women during early phase of menstrual cycle (day 1-7)

Primary hypothalamic amenorrhea: Female adults: Acetate: I.V.: 5 mcg every 90 minutes via Lutrepulse® pump kit at treatment intervals of 21 days (pump will pulsate every 90 minutes for 7 days)

LH, FSH

None reported

Antipsychotics may decrease the effects of gonadorelin

If receiving this drug via pulsating pump, check all procedures with prescriber. Report any rash, pain, or inflammation at injection site, and any change in respiratory status.

Parenteral: Dilute in 3 mL of normal saline; administer I.V. push over 30 seconds

Injection, as acetate (Lutrepulse®): 0.8 mg, 3.2 mg

Injection, as hydrochloride (Factrel®): 100 mcg, 500 mcg

Pescovitz OH, Comite F, Hench K, et al, "The NIH Experience With Precocious Puberty: Diagnostic Subgroups and Response to Short-Term Luteinizing Hormone-Releasing Hormone Analogue Therapy," J Pediatr, 1986, 108(1):47-54.